FDA Holds Off On Biogenerics Decision
In a case widely seen as a litmus test for biogenerics, the U.S. Food and Drug Administration has deferred approval of a generic recombinant DNA human growth hormone that pharmaceutical giant...To view the full article, register now.
Already a subscriber? Click here to view full article